2 May 2016 - Flamel Technologies today announced that the U.S. FDA has approved the Company’s new drug application for Akovaz (ephedrine sulphate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.

Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulphate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL.

For more details, go to: http://www.flamel.com/wp-content/uploads/2016/05/Flamel-Receives-Akovaz-Approval-20160502.pdf